Kevin Charles Gorman
Kevin Charles Gorman's purchase track record
Kevin Charles Gorman has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/13/2024 | XNCR | $1K | +6.5% | -16.5% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
XNCR: Improved Funding for Obexelimab. Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.
Transaction History
| NBIX | ▲ Buy | Grant | 14,343 | $0 | 9/11/2026 | View on chart |
| NBIX | ▼ Sell | Tax Withholding | 7,839 | $1.2M | 9/11/2026 | View on chart |
| XNCR | ▲ Buy | Grant | 10,302 | $0 | 6/16/2026 | View on chart |
| XNCR | ▼ Sell | Open Market | 7,527 | $93K | 6/15/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 205,088 | $8.9M | 5/19/2026 | View on chart |
| NBIX | ▼ Sell | Open Market | 245,088 | $37.8M | 5/19/2026 | View on chart |
| NBIX | ▼ Sell | Tax Withholding | 3,024 | $375K | 2/13/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,377 | $0 | 2/13/2026 | View on chart |
| NBIX | ▼ Sell | Tax Withholding | 2,901 | $360K | 2/13/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,604 | $0 | 2/13/2026 | View on chart |
| NBIX | ▲ Buy | Grant | 63,724 | $0 | 2/13/2026 | View on chart |
| NBIX | ▼ Sell | Tax Withholding | 34,380 | $4.3M | 2/13/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,142 | $0 | 1/31/2026 | View on chart |
| NBIX | ▼ Sell | Tax Withholding | 2,845 | $387K | 1/31/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 106,322 | $3.8M | 8/7/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 106,322 | $13.4M | 8/7/2025 | View on chart |
| XNCR | ▼ Sell | Open Market | 3,173 | $29K | 6/16/2025 | View on chart |
| XNCR | ▲ Buy | Grant | 13,686 | $0 | 6/12/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 9,613 | $1.2M | 5/27/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,603 | $0 | 2/13/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 3,012 | $351K | 2/13/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,376 | $0 | 2/13/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,832 | $330K | 2/13/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,274 | $269K | 2/10/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 4,318 | $0 | 2/8/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 5,141 | $0 | 1/31/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,707 | $414K | 1/31/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 146,105 | $4.8M | 1/27/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 146,105 | $21.8M | 1/27/2025 | View on chart |
| XNCR | ▼ Sell | Open Market | 2,654 | $55K | 9/27/2024 | View on chart |
| XNCR | ▲ Buy | Grant | 5,986 | $0 | 6/13/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 2,778 | $100K | 2/13/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 2,312 | $100K | 2/13/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,832 | $377K | 2/13/2024 | View on chart |
| XNCR | ▲ Buy | Open Market | 53 | $1K | 2/13/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,274 | $305K | 2/8/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 3,040 | $432K | 2/6/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,707 | $381K | 1/31/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 62,023 | $1.2M | 1/9/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 62,023 | $8.3M | 1/9/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 105,835 | $2.1M | 1/8/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 105,835 | $14.0M | 1/8/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 9,328 | $1.0M | 8/21/2023 | View on chart |
| XNCR | ▲ Buy | Grant | 5,007 | $0 | 6/20/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,274 | $237K | 2/8/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 3,248 | $332K | 2/7/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 20,482 | $2.1M | 2/7/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 3,040 | $321K | 2/6/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,707 | $298K | 1/31/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,274 | $181K | 2/8/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,422 | $196K | 2/7/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 3,248 | $263K | 2/7/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 3,040 | $246K | 2/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation
Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.